This report was first published by Endpoints News. To see the original version, click here
EU regulators have refused to greenlight Eli Lilly’s weight loss drug Mounjaro as a treatment for a type of heart failure, while giving the go-ahead for Novo Nordisk’s semaglutide in liver disease.
Lilly failed to get support from the European Medicines Agency’s human medicines committee, or CHMP, on Friday for Mounjaro to treat chronic heart failure with preserved ejection fraction in adults with obesity. HFpEF is when the heart becomes too stiff to pump enough blood around the body.
您已阅读16%（578字），剩余84%（3070字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。